Introduction {#s1}
============

Cystathionine ß-synthase (CBS) and cystathionine γ-lyase (CSE) are two key enzymes that are involved in the biosynthesis of hydrogen sulfide (H~2~S), a key signaling molecule that participates in various physiological functions in vertebrates (Huang and Moore, [@B11]). Endogenous H~2~S biosynthesis is also catalyzed by the coordinated action of two other enzymes cysteine aminotransferase (CAT) and 3-mercaptopyruvate sulfur transferase (3-MST). In addition to H~2~S biosynthesis, CBS and CSE enzymes also participate in transsulfuration reactions involving cystathionine (precursor to cysteine) biosynthesis through a condensation reaction of serine and homocysteine (Jhee and Kruger, [@B14]). Hyperhomocysteinemia (HHcy), a condition with elevated homocysteine is associated with mutation in the CBS enzyme (Kraus et al., [@B16]). HHcy is classified based on levels of homocysteine that range from 10.8 to 12.4 mmol/L (normal), 15 to 30 mmol/L (moderate), 31 to 100 mmol/L (intermediate), or \>100 mmol/L (severe) (Födinger et al., [@B5]). Neural tube defects resulting from failure of neural tube closure during the first 28 weeks of pregnancy remain the leading developmental disorder in these patients. Oral cleft, congenital heart defects and cardiovascular disorders were also observed in these patients. In adults, HHcy is associated with several conditions including diabetes, pulmonary embolism and Alzheimer\'s disease. Thus, CBS remains an important target that requires further understanding (Majtan et al., [@B22]).

The CBS pathway is a gateway to several essential biochemical processes including glutathione synthesis. Glutathione is a tripeptide that is synthesized from cysteine, and is vital for detoxification reaction in cells, and thus serves an anti-oxidant function. CBS generates key precursors such as cysteine, thus serving at a critical intersection point in pathways associated with endogenous detoxification mechanisms and biosynthesis of H~2~S in the cell. It is therefore not surprising that *Cbs* is critical for development and homozygous *Cbs* knockout in mice die *in utero* (Watanabe et al., [@B34]). Majority of published studies on *Cbs* knockout mice is performed on heterozygous *Cbs* background. Numerous defects ranging from vascular endothelial dysfunction (Lentz et al., [@B20]; Dayal et al., [@B3]), redox homeostasis (Vitvitsky et al., [@B32]), hyperkeratosis (Robert et al., [@B28]), endochondrial ossification (Robert et al., [@B29]), retinal neuron death (Ganapathy et al., [@B6]), lung fibrosis (Hamelet et al., [@B8]), and hepatic steatosis (Hamelet et al., [@B7]) have been reported. Majority of these defects have in part been attributed to elevated plasma homocysteine levels. A human *CBS* knock-in transgene in the endogenous mouse *Cbs* locus has also been generated, which shows elevations in plasma and tissue levels of homocysteine but shows mild hepatopathy and no hepatic steatosis or fibrosis in contrast to classical models of homcystinuria (MacLean et al., [@B21]). In lower species, such as zebrafish, gene knockdown of either *cbs* or *cse* using antisense morpholino oligonucleotides (MOs) (Porteus et al., [@B26]) influenced the hypoxic ventilatory response, an adaptation under stress conditions that allows organism to intake and process oxygen at higher rates. The oxygen-sensing neuroepithelial cells in zebrafish showed an increase in intracellular calcium concentration. The same group later reported that *cbsb* knockdown using morpholinos (MOs) and not *cse* showed a reduction in calcium influx in larval zebrafish (Kwong and Perry, [@B18]). In addition to calcium, larval zebrafish containing gene knockdowns of *cse* and *cbsb* (Kumai et al., [@B17]) showed better sodium uptake. Collectively, these results argue for a role for *cbsb* in maintaining H~2~S and homocysteine homeostasis in developing embryos. However, the consequence of altering H~2~S and homocysteine homeostasis via modulation of *cbsb* during zebrafish embryonic development is unknown. Here, we performed a systematic and detailed analysis into Cbs enzyme role in zebrafish embryonic development, and its role in maintaining H~2~S and homocysteine homeostasis *in vivo*. Because of genome duplication in zebrafish, a significant portion of the genes in zebrafish have duplicates (Postlethwait et al., [@B27]). For the *cbs* gene, of the two orthologs *cbsa* and *cbsb* in zebrafish, we postulated that the *cbsb* gene was critical for embryonic development because of prior *in situ* hybridization (ISH) pattern data observed on zebrafish information network site. To investigate this hypothesis, we performed RNA analysis and whole mount ISH (WISH) across embryonic stages. We also performed loss-of-function analysis using MOs (Ekker, [@B4]) and CRISPR/Cas9 (Hruscha et al., [@B10])-based genomic engineering approaches. Finally, we performed rescue for the loss-of-function phenotypes using small molecules that modulate the H~2~S and cysteine biosynthesis pathway. Our study here points to a critical role for *cbsb* in embryonic axis development.

Materials and methods {#s2}
=====================

Zebrafish
---------

All zebrafish studies performed here were carried under the AUA protocol 320, which is approved by the MCW institutional animal care and use committee. Embryo stages were performed as per the zebrafish book and whole mount *in situ* hybridization with anti-sense and sense digoxigenin probes were carried out based on protocols published before (Bedell et al., [@B1]; Thisse and Thisse, [@B30]).

Chemicals
---------

GYY4137 (P-(4-Methoxyphenyl)-P-4-morpholinyl-phosphinodithioic acid), NaSH.xH~2~O (sodium hydrosulfide hydrate) and betaine (Trimethylglycine) chemicals were purchased from Sigma Aldrich. 1 M Stock solution of GYY4137 was prepared in dimethylsulfoxide (DMSO) and stored at 4°C. 50 mg/ml solution of betaine was prepared in water and stored at 4°C. 1 M stock solution of NaSH.xH~2~O was prepared in water and used immediately.

Molecular biology
-----------------

Probes for sense and anti-sense *cbsa* and *cbsb* were generated using PCR-based methods. The primers for these probes include:

*Cbsa* sense: Fwd 5′-CACCGAAATAATACGACTCACTATAGGGGATGGAGACAGACCCCCACA, Rev 5′-GGCACTTTTCCTTCAATTTCCGA and antisense primers: Fwd 5′- GATGGAGACAGACCCCCACA, Rev 5′ CACCGAAATTAACCCTCACTAAAGGGGGCACTTTTCCTTCAATTTCCGA

*Cbsb* sense: Fwd 5′-CACCGAAATAATACGACTCACTATAGGGATCAACGGGGATGCTGACGAT, Rev 5′- CAATCTCAGCACCCAGAGCA and antisense primers: Fwd 5′- ATCAACGGGGATGCTGACGAT, Rev 5′- CACCGAAATTAACCCTCACTAAAGGGCAATCTCAGCACCCAGAGCA

Primer sequences used for amplification include:

*Cbsa*, Fwd 5′- GATGGAGACAGACCCCCACA, Rev 5′- GGCACTTTTCCTTCAATTTCCGA

*Cbsb*, Fwd 5′- ATCAACGGGGATGCTGACGAT, Rev 5′- CAATCTCAGCACCCAGAGCA

Actin (*actb1*): Fwd 5′- GAAATTGTCCGTGACATCAA, Rev 5′- CACTGTGTTGGCATACAGGT

Western blotting and IF
-----------------------

For western blotting, 48 h post fertilization (hpf) CBSB-S1-injected, ConMO-injected and *cbsb* CRISPR embryos were dechorionated and then de-yolked in PBS. Total cell lysate was prepared in radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors. Measurement of protein concentration was performed using BCA assay kit from Pierce, Grand Island, NY, USA. SDS-PAGE and immunoblotting was performed using standard protocol. The cell lysates were separated on 10% glycine SDS-PAGE gel and transferred to PVDF membrane. Membranes were blocked in 5% BSA in TBS with 0.1% TWEEN-20 (TBST) for 1 h at room temperature followed by incubation with indicated primary antibodies in TBST with 5% BSA. Antibodies were purchased from following vendors. CBS (D8F2P) purified rabbit antibody (catalog \#14782, Cell Signaling Technology, MA) was used at a 1:1000 dilution; anti-GAPDH antibody (Sigma-Aldrich, MO) was used at a 1:5,000 dilution at 4°C overnight. Horseradish peroxidase conjugated secondary antibodies were used and proteins were visualized by Clarity Western ECL Substrate (Bio-Rad). For the immunofluorescence experiment, CBSB-S1-injected embryos, ConMO-injected embryos and *cbsb*-CRISPR embryos were dechorionated at 48 hpf and fixed with 4% paraformaldehyde in phosphate buffered saline (PBS) at 4°C overnight. The following day, embryos were washed twice with PBST (PBS, 0.1% (v/v) Tween 20), permeabilized in ice-cold acetone for 10 min and washed in PBST. Embryos were blocked in 10% normal goat serum for 1 h and incubated with purified rabbit anti-homocysteine antibody (Catalog \# ab15154, Abcam, MA) overnight at 4°C. Embryos were washed twice with PBST, incubated with the appropriate secondary antibody (Alexa fluor 568 goat anti-rabbit, Invitrogen, MA) for 2 h at RT, washed with PBST and imaged on a Zeiss AxioObserver Z1 fluorescence inverted microscope.

Morpholino studies
------------------

Gene Tools, Inc. designed all the morpholinos. Sequence is provided (**Figure 2C**). Control MO sequence used in this study is 5′-CCTCTTACCTCAGTTACAATTTATA-3′. All MOs were each injected into Transgenic (Tg: *flk*:EGFP) (Choi et al., [@B2]) one cell stage embryos. The 1 mM MO stock solutions were diluted to a final concentration of 2 ng/nL (250 μM), and appropriate concentrations as shown in the figure panels were injected into each embryo. For phenotypic imaging, 30 and 52 hpf embryos were anesthetized in 0.02% tricaine, mounted on a depression slide, and imaged with a Zeiss Stemi 2000-C dissecting microscope.

H~2~S measurement studies
-------------------------

H~2~S was measured according to the published protocol (Papapetropoulos et al., [@B24]). Briefly, ConMO-injected and CBSB-S1-injected zebrafish embryos were collected by centrifugation and re-suspended in a total volume of 200 μL of PBS (pH 7.4), and 100 μL was then transferred directly into a tube containing zinc acetate (1% wt/vol, 187.5 μl) and NaOH (12%, 12.5 μL) to trap the H~2~S for 20 min at room temperature. The rest of the embryo suspension was used to estimate protein concentration by BCA assay. The reaction was terminated by adding 1 mL of H~2~O (pH 12.8), 200 μL of N, N-dimethyl-p-phenylenediamine sulfate (20 mM in 7.2 M HCl), and 200 μL of FeCl~3~ (30 mM in 1.2 M HCl). The mixture was incubated at room temperature in darkness for 15 min, and finally 600 μL of the mixture was added to a tube with 150 μL of trichloroacetic acid (10% wt/vol) to precipitate protein. The precipitated protein was removed by centrifugation at 10,000 g for 5 min, and absorbance at 670 nm of the resulting supernatant (200 μL) was determined. The H~2~S concentration of each sample was calculated against a calibration curve of NaHS.

Small molecule studies
----------------------

CBSB-S1 injected or *cbsb* CRISPR embryos were treated with either 1 mM betaine or 1 mM GYY4137 or 1 mM NaHS at 6 hpf. All embryos were then developed to 30 or 52 hpf in the 28°C incubator. Pictures were taken as described earlier.

CRISPR studies
--------------

CRISPR/CAS9 target sequences were designed using E-CRISP. (Heigwer et al., [@B9]). pT3TS-nCas9n was a gift from Wenbiao Chen (Addgene plasmid \# 46757) (Jao et al., [@B12]). sgRNA and capped *cas9* mRNA were synthesized by *in-vitro* transcription as previously described. (Varshney et al., [@B31]) The *cbsb* sgRNA was validated by the Guide-it™ sgRNA Screening Kit from Clontech. One-cell stage embryos were injected with 250 pg of sgRNA and 250 pg of *cas9* mRNA. Injected founder (F~0~) fish were fin-clipped at adulthood and screened for INDELs at the target location by Sanger sequencing. Two F~0~ founders containing the same 2 base pair deletion at the target site were bred to produce F~1~ mutants (lines C, H, and F). F~1~ mutants were raised to adulthood and in-crossed for production of F~2~ embryos, for which phenotypes were observed and quantified. For rescue, CRISPR embryos were placed in 1 mM betaine at 6 hpf. CRISPR phenotypes were evaluated at 5 dpf. All CRISPR lines were generated in the background of (Tg: *flk*:EGFP) (Choi et al., [@B2]) and CASPER (Zebrafish Information Resource Center), and is referred to as *flk*:EGFP CASPER in this study.

Quantification details and statistics
-------------------------------------

### Embryo length determination

Body length was measured from the tip of the head to the end of the trunk. Scale bar calibration and length measurements were done with a Leica MZFL III microscope using a stage micrometer and Q-Capture PRO 7 software. *T*-test was performed using graph pad prism program on **Figures 2E**, **3F**, **4D**, **5**, **6**. Data are plotted as mean values and error bars indicate standard error of the mean. The standard *t*-test was used to evaluate statistical significance. A *p*-value \< 0.05 was considered significant and *p*-values \< 0.01, 0.001, 0.0001 were considered very significant.

Results {#s3}
=======

Expression analysis of *cbsa* and *cbsb* genes during embryonic development
---------------------------------------------------------------------------

We first performed reverse transcription-based PCR (RT-PCR) using gene-specific primers for *cbsa, cbsb* and *actin* genes using RNA isolated from 2, 6, 10, 18, 24, 28, 36, 48, and 72 hpf embryos (Figure [S1](#SM1){ref-type="supplementary-material"}). Both *cbsa* and *cbsb* genes are maternally expressed and showed expression in 2 hpf embryo, which continued throughout all stages of development. The *cbsa* transcript is initially expressed minimally, but its expression begins to increase around 18 hpf (Figure [S1](#SM1){ref-type="supplementary-material"}). Notably, the *cbsb* expression peaks at end of gastrulation (10 hpf) stage, and the expression is constitutive in the remaining period of development (Figure [S1](#SM1){ref-type="supplementary-material"}). To detect the location of *cbsb* transcripts, we performed WISH using digoxigenin-labeled sense and antisense RNA probes at the bud stage, 18, 24, and 48 hpf (Figure [1](#F1){ref-type="fig"}). *Cbsb* expression is noticeably visible in the embryonic axis in the early tail bud stage (Figures [1A--C](#F1){ref-type="fig"}), an early indication of the importance of *cbsb* in axis development. At 18 hpf, *cbsb* expression is visible in the head region in the entire brain (Figure [1D](#F1){ref-type="fig"}) and in the somites in the body axis (Figure [1D](#F1){ref-type="fig"}′). At 24 hpf (Figures [1F,F](#F1){ref-type="fig"}′), *cbsb* expression pattern continues in the somites (Figure [1F](#F1){ref-type="fig"}), while in the head, expression shifts from the brain to the 4th ventricle highlighting the dynamic role of *cbsb* in early brain development. At this stage, sense probe controls do not show staining (Figure [1E](#F1){ref-type="fig"}). At 48 hpf, the expression of *cbsb* continues in both the brain and the 4th ventricle in the head as well as the somites in the trunk (Figures [1H,H](#F1){ref-type="fig"}′). WISH for *cbsa* was also performed at 24 hpf, a stage at which expression for *cbsa* was robust in RT-PCR results (Figure [S1](#SM1){ref-type="supplementary-material"}). *Cbsa* gene shows strong expression in the entire head, and in the trunk region (Figure [1G](#F1){ref-type="fig"}), particularly in the somites. Taken together, the expression data suggests that *cbsa* and *cbsb* genes are ubiquitously expressed throughout the head and in the somites, and suggest a role in head and axis development.

![ISH analysis of *cbsa* and *cbsb* genes in zebrafish embryos. **(A--G)** are digioxigenin-labeled whole mount *in situ* hybridization for *cbsa* and *cbsb* RNA. Panels **(A--C)** are bud stage, (**D,F,H)** are 18, 24, and 48 hpf embryos respectively, Panels **(D--H**′**)** are high power images of the respective **(D,F,H)**. Panel **(E)** is a *cbsb* sense probed 24 hpf embryo, and Panel **(G)** is a *cbsa* antisense probed embryo at 24 hpf. Scale bars indicate 0.25 mm.](fcell-06-00014-g0001){#F1}

Loss of function of *cbsb* but not *cbsa* affects embryonic axis development
----------------------------------------------------------------------------

To investigate function of *cbsa* and *cbsb*, we employed two strategies, morpholinos (MOs) and CRISPR/Cas9 genomic engineering methods. We designed MOs that targeted *cbsa* and *cbsb* (Figure [2A](#F2){ref-type="fig"}) genes at specific splice junctions \[*cbsa*: intron 4-exon 5 (CBSA-S1); *cbsb*: intron 2-exon3 (CBSB-S1), exon3-intron3 (CBSB-S2), and intron4-exon5 (CBSB-S3)\]. MO sequences are provided (Figure [2C](#F2){ref-type="fig"}). Efficacy of MOs were determined at the RNA (Figure [2B](#F2){ref-type="fig"}) and protein (Figure [2D](#F2){ref-type="fig"}) level. CBSA-S1 indeed induced an alteration in *cbsa* transcript with no change in *cbsb* transcript (Figure [2B](#F2){ref-type="fig"}). Of the three splice MOs for *cbsb*, CBSB-S1 injected embryos produced a smaller alternate band (Figure [2B](#F2){ref-type="fig"}). The band was extracted and sequenced, which revealed that exon 3 was missing (data not shown). Importantly, *cbsa* mRNA in CBSB-S1-injected embryos did not show consistent change relative to WT or conMO lanes (Figure [2B](#F2){ref-type="fig"}, and data not shown). Similarly, CBSB-S2 and -S3 MOs did target *cbsb* and not *cbsa* (Figure [2B](#F2){ref-type="fig"}), but concentrations of MOs required to achieve this effect was high. Therefore, for *cbsb*, we eventually settled on CBSB-S1 MO, which produced consistent loss of native *cbsb* full-length transcript. We also investigated protein changes in the embryo lysates, and observed consistent down regulation of CBSB protein at 24 and 48 hpf (Figure [2D](#F2){ref-type="fig"}). Because CBS is an enzyme the catalyzes the production of H~2~S gas via a reaction where cysteine combines with homocysteine to form cystathionine (Wallace and Wang, [@B33]), we measured H~2~S levels in CBSB-S1 MO-injected and control MO (ConMO)-injected embryos. CBSB-S1 MO1 knockdown embryos showed reduction in H~2~S levels compared to their control counterparts (Figure [2E](#F2){ref-type="fig"}, ^\*^*p* \< 0.01).

![Loss-of-function efficacy studies. Panel **(A)** shows a "partial" cartoon representation of the *cbsb* genomic site with the location of the MO sites (purple rectangles) at appropriate intron (i) and exon (e) junctions, CRISPR-targeted site (red rectangle), site of RT-PCR forward **(F)** and reverse primers, and the antibody recognition site. Panel **(B)** shows RT-PCR for three genes (*cbsb, cbsa, actin*) in total RNA from injected embryos (\~24 hpf) (left to right): wild type (WT) control and *cbsb* CRISPR-injected fish, *cbsa* splice 1 (CBSA-S1), control morpholino (ConMO), *cbsb* splice1 (CBSB-S1), *cbsb* splice 2 (CBSB-S2), *cbsb* splice 3 (CBSB-S3). Panel **(C)** shows the sequence of the morpholinos used in this study. Panel **(D)** shows CBS and GAPDH western blots for ConMO, CBSB-S1 at 24 and 48 hpf along with control and *cbsb* CRISPR fish at 48 hpf. Panel **(E)** shows the comparison between CBSB-S1 MO and ConMO-injected embryos for hydrogen sulfide production. *n* = 3 for both groups (data from three experiments). Twenty embryos in each group in each experiment. ^\*\*^*P* \< 0.01.](fcell-06-00014-g0002){#F2}

The WISH analysis suggested redundant functions for *cbsa* and *cbsb* in embryonic development. CBSA-S1 alone injected embryos showed no phenotype (data not shown). CBSB-S1 when injected alone into 1-cell stage zebrafish embryos showed a shortened anterior-posterior axis and head edema (Figures [3B--D](#F3){ref-type="fig"}) compared to ConMO-injected embryos at 30 hpf (Figure [3A](#F3){ref-type="fig"}). Therefore, we concluded that all effects were observed due to *cbsb* loss-of-function. A dose-dependent increase in severity of the bent axis and brain edema phenotypes was observed (Figures [3B--D](#F3){ref-type="fig"}), which was quantified (bent axis, Figure [3E](#F3){ref-type="fig"}, ^\*\*\*\*^*P* \< 0.0001; brain edema, Figure [3F](#F3){ref-type="fig"}, ^\*\*\*\*^*P* \< 0.0001), and correlated well with percentage mortality (Figure [3G](#F3){ref-type="fig"}, ^\*\*^*P* \< 0.01). At \~50 hpf, the axis defects were pronounced in CBSB-S1-injected embryos (Figure [4A](#F4){ref-type="fig"}) compared to ConMO-injected embryos (Figure [4B](#F4){ref-type="fig"}), and phenotype expressivity varied from moderate to severe phenotypes (Figure [4C](#F4){ref-type="fig"} and Figure [S2](#SM1){ref-type="supplementary-material"}). The axis length was measured and showed decrease in CBSB-S1-injected embryos compared to controls (Figure [4D](#F4){ref-type="fig"}, ^\*\*\*\*^*P* \< 0.0001). We also investigated the vasculature grossly since we injected CBSB-S1 into transgenic embryos where VEGFR2 promoter or fms-like kinase (FLK) drives enhanced green fluorescent protein (EGFP) \[Tg (*flk:*EGFP)\] expression (Choi et al., [@B2]) in the vasculature. We did not observe much changes to the major vessels in CBSB-S1-injected embryos compared to ConMO-injected embryos (Figure [S3](#SM1){ref-type="supplementary-material"}). These results suggest that *cbsb* is important for axis development.

![Dose-dependent effect of *cbsb* morpholinos at 30 hpf. Phase contrast images of 30 hpf embryos injected with 4 ng of control (Con) MO **(A)**; 1 ng *cbsb* splice1 (CBSB-S1) MO **(B)**; 2 ng (CBSB-S1) **(C)** and 4 ng (CBSB-S1) **(D)** are shown. Arrow shows brain edema. Panels **(E,F)** quantifies the number of CBSA-S1 MO-injected embryos displaying bent axis, and brain edema (black arrows) compared to ConMO-injected embryos. *n* = 186 surviving embryos for CBSB-S1 MO and *n* = 272 surviving embryos for ConMO, which were a total of four experiments ^\*\*\*\*^*P* \< 0.0001 for both bent axis phenotype and brain edema phenotype. **(G)** Percentage survival observed over a 5 day period for three different doses of CBSB-S1-injected (1 ng, *n* = 70; 2 ng, *n* = 70; 4 ng, *n* = 70) and ConMO-injected embryos (4 ng, *n* = 70), *n* = 6 time points, ^\*\*^*P* \< 0.01 for comparison between ConMO and each of the respective CBSB-S1 MO doses. Scale bars indicate 0.25 mm.](fcell-06-00014-g0003){#F3}

![*cbsb* morphant phenotype at 52 hpf. Low magnification images of 52 hpf Tg (*flk*:EGFP) embryos injected with 2 ng CBSB-S1 **(A)** and 2 ng control (Con) MO are shown. Panel **(C)** shows various phenotypes observed from mild to server for CBSB-S1 at 52 hpf. Note the progressive loss of axis length. Panel **(D)** shows quantification of the length of the axis is shown in **(A)**. Y-axis shows mean length of the embryo measured as the longest horizontal dimension between the start of the yolk and the end of the tail (*n* = 11 for CBSB-S1 and ConMO-injected embryos), ^\*\*\*\*^*P* \< 0.0001. In the figure panels, the embryo orientation is left is anterior (A) and right is posterior (P) while top is dorsal (D) and bottom is ventral (V). Scale bars indicate 0.25 mm.](fcell-06-00014-g0004){#F4}

*cbsb* CRISPR-modified embryos phenocopy *cbSb* MO
--------------------------------------------------

To complement MO loss-of-function analysis, we generated guide RNAs (gRNAs) that target exon 4 of *cbsb* gene (Figure [4A](#F4){ref-type="fig"} and Figure [S4A](#SM1){ref-type="supplementary-material"}). Guide RNA efficacy was demonstrated (Figure [S4B](#SM1){ref-type="supplementary-material"}), and gRNA + Cas9 injected fish were genotyped for genomic modifications (Figure [S4C](#SM1){ref-type="supplementary-material"}). Indeed, 35.4% of the gRNA/Cas9-injected F0 fish showed 2 bp deletions, and several showed deletions and point mutations (Figure [S4C](#SM1){ref-type="supplementary-material"}). Also, *cbsb* RNA was lower and no change in *cbsa* RNA was observed in *cbsb* CRISPR fish when compared to control fish (Figure [2B](#F2){ref-type="fig"}). The CBS protein level was lower (Figure [2D](#F2){ref-type="fig"}) in *cbsb* CRISPR fish compared to control fish. We raised the F0 *cbsb* CRISPR fish and generated three independent *cbsb* CRISPR fish lines (C, H, and K). Three distinct axis phenotypes were observed (Figure [5](#F5){ref-type="fig"}), which were categorized as mild, medium and severe. Phenotypes were readily visible at 48 hpf with a bent axis and tail. In extreme cases, the axis was severely truncated (Figure [5](#F5){ref-type="fig"}, severe phenotype) similar to CBSB-S1 embryos (Figure [S2](#SM1){ref-type="supplementary-material"}). The phenotype progressed and became evident by 72 and 120 hpf. It is noteworthy that the bent in the axis resulted in alterations of tail to upward or downward orientation. Quantification of the axis phenotype severity for CRISPR fish in three independent lines (Figure [5D](#F5){ref-type="fig"}) showed \~30% of defective embryos per line. Based on *t*-test analysis of the data from 5 independent experiments (Figure [5D](#F5){ref-type="fig"}), the differences between the percentage of embryos with bent axis in each of the *cbsb* CRISPR lines (C, ^\*^*P* \< 0.05; H and K, ^\*\*\*^*P* \< 0.001) was found to be statistically significant compared to the percentage of embryos with bent axis in the control *flk*:EGFP CASPER line. These results show that *cbsb* is mainly responsible for axis development in zebrafish.

![*cbsb* CRISPR embryos show axis defects. Control *flk*:EGFP CASPER embryos are shown at 48 hpf **(A)**, 72 **(B)**, and 120 hpf **(C)**. *cbsb* CRISPR embryos are shown at 48 hpf **(A**′**-A**‴**)**, 72 hpf **(B**′**-B**‴**)**, and 120 hpf **(C**′**,C**″**)**. Mild, medium, and severe phenotypes are shown for each time point for the *cbsb* CRISPR embryos except at 120 hpf. Panel **(D)** shows quantification of the axis defects in three independent CRISPR lines (C, H, and K) and comparison of the axis defects with control *flk*:EGFP CASPER line. Y axis shows the average of the percentage of embryos from five experiments with bent axis and normal axis. *n* = 311 embryos for C line, *n* = 236 embryos for H line, *n* = 241 embryos for K line and *n* = 311 embryos for the control *flk*:EGFP CASPER line which are total number of embryos from five independent experiments. To perform statistical analysis, embryos showing any degree of bent axis phenotype (mild, medium, or severe) have been grouped together into one category called bent axis. ^\*^*P* \< 0.05 for comparison of percent embryos with bent axis between controls and CRISPR line C, ^\*\*\*^*P* \< 0.001 for comparison of percent embryos with bent axis between controls and CRISPR line H and ^\*\*\*^*P* \< 0.001 for comparison of percent embryos with bent axis between controls and CRISPR line K. In the figure panels, the embryo orientation is left is anterior (A) and right is posterior (P) while top is dorsal (D) and bottom is ventral (V). Scale bars in the 48 and 72 hpf panels indicate 0.25 mm; scale bars in 120 hpf panels **(C--C**″**)** are 0.4 mm. Error bars indicate standard error of the mean of five experiments.](fcell-06-00014-g0005){#F5}

Rescue of *cbsb* axis phenotype with small molecules
----------------------------------------------------

Because CBSB is a critical enzyme in cysteine & H~2~S metabolism (Figure [S5](#SM1){ref-type="supplementary-material"}), we investigated whether small molecules that influence these pathways would rescue the axis phenotype. We treated CBSB-S1-injected embryos with small molecules that rescue loss or gain of specific products in the CBSB enzyme pathway. Hydrogen sulfide (H~2~S) is an important byproduct of cysteine metabolism, and was observed to be lower in CBSB-S1 knockdown embryos (Figure [2E](#F2){ref-type="fig"}). We treated CBSB-S1-injected embryos at 6 hpf with two H~2~S donor compounds \[Sodium hydrosulfide (NaHS), & GYY4137 (Figure [S6](#SM1){ref-type="supplementary-material"})\], and investigated whether replenishment of H~2~S would rescue the *cbsb* morphant phenotype. NaHS is an immediate H~2~S releasing compound while GYY4137 is a slow-releasing H~2~S donor. Intriguingly, GYY4137 (Figures [6C,C](#F6){ref-type="fig"}′) rescues the head edema and axis defects at 52 hpf while NaHS (Figure [6D](#F6){ref-type="fig"}) does not rescue these phenotypes suggesting that a long-term release of H~2~S is necessary for CBS enzyme function. *Cbs* deficiency also causes increase in homocysteine levels (Jhee and Kruger, [@B14]), Therefore, drug betaine that lowers homocysteine levels was tested, which rescued the axis defect at 52 hpf (Figure [6E](#F6){ref-type="fig"}′) but not the head edema (Figure [6E](#F6){ref-type="fig"}, black asterisk). This result along with the GYY4137 result suggests that embryonic axis defect is sensitive to loss of H~2~S and increase in homocysteine levels. Quantification is shown in Figure [6F](#F6){ref-type="fig"}.

![Rescue of *cbsb* phenotypes using small molecules at 30 and 52 hpf. All embryos were injected to 2 ng of cbsb-splice1 (CBSB-S1) or control (Con) morpholinos (MOs). Panels **(A--E)** are 30 hpf phase contrast images, and corresponding **(A**′**-E**′**)** are 52 hpf images. Panels **(A,A**′**)** is an untreated embryo injected with CBSB-S1 MO, which shows distinct phenotypes including head edema, and axis defect. Panels **(B,B**′**)** are ConMO-injected embryo. Panels **(C,C**′**)** are CBSB-S1-injected embryo treated with 1 mM GYY4137, which rescues the head edema and axis defects. Panels **(D,D**′**)** are CBSB-S1-injected embryo treated with 0.5 mM NaHS, which does not rescue the phenotype. Panels **(E,E**′**)** are CBSB-S1 injected embryo treated with 1 mM betaine, which rescues the axis defect but not the head edema (black asterisk). Panel **(F)** shows quantification of the rescue of bent axis and head edema phenotypes for CBSB-S1 MO-injected embryos. Y axis shows percentage of embryos with bent axis phenotypes and head edema phenotypes (average of three experiments). Three experiments were performed. X axis categories: Untreated *n* = 118 embryos, NaHS treated *n* = 111 embryos, Betaine treated *n* = 120 embryos and GYY4137 treated *n* = 121 embryos which are total number of embryos for 3 experiments. ^\*\*\*^*P* \< 0.0001 for comparison between untreated and betaine treated for bent axis phenotypes. ^\*\*\*^*P* \< 0.0001 for comparison between untreated and GYY4137 treated for both bent axis and head edema phenotypes. Error bars indicate standard error of the mean of three experiments. Panel **(G)** shows quantification of *cbsb* CRISPR lines (C, H, and K) for the betaine rescue of axis defects at 5 dpf. For statistical analysis, all embryos with bent axis (irrespective of severity: mild, medium, and severe) were placed into one category bent axis. Y axis shows average of percentage of embryos (with bent axis or normal axis) from three experiments. *n* = 114 For C Untreated, *n* = 120 for H Untreated, *n* = 112 for K Untreated, *n* = 121 for Controls Untreated, *n* = 120 for C + Betaine, *n* = 119 for H + Betaine, *n* = 124 for K + Betaine and *n* = 117 for Controls + Betaine, which are total number of embryos from 3 independent experiments. *T*-test analysis resulted in ^\*\*^*P* \< 0.001 for comparisons between untreated *cbsb* CRISPR lines and *cbsb* CRISPR lines treated with betaine. (C vs. C + Betaine, H vs. H + Betaine, K vs. K + Betaine). Differences between control and control + Betaine groups were not statistically significant. Error bars indicate standard error of the mean of three experiments.](fcell-06-00014-g0006){#F6}

Based on *t*-test analysis of data from 3 independent experiments (Figure [6F](#F6){ref-type="fig"}), the differences between untreated morphant embryos and morphant embryos treated with betaine were found to be statistically very significant (^\*\*\*^*P* \< 0.0001) for the bent axis phenotype. Similarly, the differences between untreated morphant embryos and morphant embryos treated with GYY4137 were found to be statistically very significant (^\*\*\*^*P* \< 0.0001) for both the bent axis phenotype and head edema phenotype. We also treated *cbsb* CRISPR fish lines with betaine (Figure [6G](#F6){ref-type="fig"}), which resulted in loss of severe and medium axis phenotype in all three lines, and reduction in the total % of embryos displaying phenotype. For Figure [6G](#F6){ref-type="fig"}, based on data from 3 independent experiments, *t*-test analysis showed that the differences between the untreated and treated groups for the three CRISPR lines (C Untreated compared to C+Betaine; H Untreated compared to H+Betaine; K Untreated compared to K+Betaine) were statistically very significant (^\*\*\*^*P* \< 0.001). The differences between the Controls Untreated and Controls + Betaine groups were not statistically significant.

Discussion {#s4}
==========

This manuscript reports the importance of Cbsb enzyme in maintaining H~2~S homeostasis during embryonic zebrafish development. The salient features include, the characterization of the expression of *cbsa* and *cbsb* transcripts during embryonic development, the loss-of-function analysis using two complementary independent approaches, and finally the rescue of the axis phenotype with small molecules that are used for treatment of CBSB enzyme deficiency in the clinic.

The RNA expression pattern for *cbsa* and *cbsb* across developmental stages shows that *cbsb* is the dominant gene in terms of its levels, which later also is the case for function. The expression of *cbsb* is observed as early as bud stage (10 hpf) along the developing embryonic axis, and continues through 24 and 48 hpf along the anterior-posterior axis of the embryo. *Cbsb* expression is prominent in the brain and somite muscle, two tissues that are highly susceptible to changes in H~2~S levels during normal physiology.

Our approach to assess function of *cbsb* was to use complementary methods such as MOs and CRISPR-Cas9. Given the evidence that MOs induced phenotypes do not replicate fully in genetic mutants (Kok et al., [@B15]), we only focused on phenotypes that were observed routinely under both loss-of-function conditions. One main difference between the two approaches is that the splice1 MO (CBSB-S1) targets exon 3 while *cbsb* CRISPR targets exon 4 of *cbsb* gene. In the morphants, we did observe head edema and axis defect. Because *cbsb* CRISPR embryos only showed anterior-posterior shorter axis defect, we reasoned that axis defect as the primary defect for loss of *cbsb* function during development. It is reasonable to argue that head edema is a secondary effect related to extremely high levels of homocysteine (Figure [S7](#SM1){ref-type="supplementary-material"}) and methionine in the brain, which is presumed to occur with CBS enzyme deficiency (Figure [S5](#SM1){ref-type="supplementary-material"}). However, our results and those from others collectively argue against the secondary effect possibility. For example, patients with *CBS* deficiency who were treated with betaine therapy showed cerebral edema (Yaghmai et al., [@B35]). Consistent with this observation, treatment of CBSB-S1 embryos with betaine, a molecule known to reduce homocysteine levels and increase methionine levels in plasma failed to rescue head edema (Figure [6F](#F6){ref-type="fig"}). Thus, the edema seems to be an upstream effect of homocysteine levels in the brain, perhaps increased methionine. Homocysteine and methionine are also products of folate-mediated one carbon cycle, and evidence exists in zebrafish that folate pathway disruption in zebrafish (Lee et al., [@B19]) causes developmental delays including shortened axis development. Folate also known as vitamin B~9~ is a co-factor for enzymes involved in transmethylation reactions and *de novo* synthesis of purines and thymidylate. These products are critical for DNA replication and thus cell cycle-associated events in a developing embryo. Pathway disruption in folate leads to disruption in thymidylate levels, which in turn affects dTTP thus lengthening the cell cycle in the developing embryo (Lee et al., [@B19]). This delay in S-phase along with the observed increase in apoptosis in these embryonic cells in zebrafish results in fewer cells in the embryo that are necessary for organism development including axis formation. Our results suggest that alteration of products (homocysteine and methionine) shared by the transsulfuration and folate pathways predictably show similar consequence in a developing embryo, namely shortened axis development. This interconnection provides one mechanistic explanation to our findings, and requires further exploration in the context of embryonic development.

Previous work has shown that small molecule slow releasing H~2~S donor GYY4137 treated for 4 days in zebrafish larvae significantly reduced sodium uptake (Kumai et al., [@B17]), and this reduced sodium uptake was rescued when CBS or CSE was pharmacologically inhibited. In our study, GYY4137 rescues both axis and edema defects associated with loss of *cbsb*. Taken together, this implies that GYY4137 influences CBSB enzyme directly or indirectly to influence sodium uptake in cells of a developing embryo, and this influence is critical for restoring homeostasis in embryo, which includes proliferation and apoptosis of cells that are necessary for axis formation. In addition to H~2~S, gases such as nitric oxide (NO), and carbon monoxide (CO) collectively referred to as gasotransmitters interact leading to oxidative stress in the developing embryo (Olson et al., [@B23]). These gases have already been implicated in control of breathing and ion regulation in fish (Perry et al., [@B25]). NO also has profound effects on neuromuscular properties in zebrafish (Jay et al., [@B13]), which directly correlates to trunk axis structural integrity. Thus, future work will focus on identifying the interactions of gasotransmitters and the mechanisms that they associate with in facilitating embryonic growth and development.

In summary, we have identified a novel phenotype for *cbsb* in zebrafish using multiple approaches, and have demonstrated that *cbsb* is partly responsible for anterior-posterior axis development in zebrafish. A combination of homocysteine and H~2~S regulation is responsible for the axis development, and structures along the axis of the embryos are highly susceptible to this regulation.

Author contributions {#s5}
====================

SP designed and performed experiments, interpreted data, wrote, and edited the manuscript; CK designed and performed experiments, and interpreted data, wrote, and edited the manuscript; AD designed and performed experiments, and interpreted data; SE-B designed and performed experiments, and interpreted data; NL performed experiments and interpreted data; RB provided intellectual input, direction in experimental design, and edited the manuscript; PM provided intellectual input, direction in experimental design, provided resources, and edited the manuscript; RR provided intellectual input, direction in experimental design, provided resources, and wrote the manuscript.

Conflict of interest statement
------------------------------

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We thank Developmental Vascular Biology Program members for their input and suggestions.

**Funding.** This work was supported by a MPI grant from National Institutes of Health (1R01HL120585) to PM and RB with a subcontract to RR at MCW. PM is also supported by 2R01CA136494. RR is also supported by 1R01HL112639, 1R01HL120585, and 1R01HL123338, and partly supported by funds from Women\'s Health Research Program at MCW. SP and CK are supported by Department of Pediatrics and Children\'s Research Institute funds to RR. SE-B is supported by funds from Kelleigh\'s Cause Foundation.

Supplementary material {#s6}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcell.2018.00014/full#supplementary-material>

###### 

Click here for additional data file.

[^1]: Edited by: Gregory Kelly, University of Western Ontario, Canada

[^2]: Reviewed by: John Hancock, University of the West of England, United Kingdom; Rodrigo Franco, University of Nebraska-Lincoln, United States

[^3]: This article was submitted to Signaling, a section of the journal Frontiers in Cell and Developmental Biology

[^4]: †These authors have contributed equally to this work.
